1. Introduction {#sec1}
===============

A characteristic feature of type 2 diabetes is increased endogenous glucose production, largely due to increased hepatic glucose production (HGP) [@bib1; @bib2; @bib3; @bib4]. Two rate-limiting enzymes of HGP are glucose 6-phosphatase catalytic subunit (encoded by *G6PC*) and phosphoenolpyruvate carboxykinase (encoded by *PCK1* and *PCK2*). As the expression of these enzymes is suppressed by insulin, it has been widely held that patients with type 2 diabetes (T2D) would have increased expression of *G6PC* and *PCK*, due to hepatic insulin resistance. However, it has been challenging to correlate expression of these enzymes with diabetes or glycemia in humans [@bib5; @bib6].

Another determinant of hepatic glucose homeostasis is glucokinase (encoded by *GCK*). G6PC and GCK act in opposition to regulate the intracellular levels of free glucose; thus, the coordinated regulation of these two enzymes ultimately determines the gradient and flux of glucose into or out of the hepatocyte [@bib7]. An increased ratio of G6PC/GCK, as occurs during fasting, causes glucose efflux to the bloodstream, whereas a decreased ratio causes increased influx.

Previous work has indicated that GCK activity is decreased in type 2 diabetes [@bib8; @bib9; @bib10; @bib11; @bib12]. Although mutations in the GCK gene cause maturity onset diabetes of the young type 2 (MODY2), GCK mutations are not found in the etiology of classical T2D. Thus, the decrease in GCK activity is likely due to transcriptional or posttranslational effects. However, the expression of liver *GCK* during T2D has not yet been established.

In this study, we investigated the contribution of *GCK*, *G6PC*, and *PCK* expression to glycemia in diabetes. We examined liver tissue from 40 obese subjects: 12 had normal glucose tolerance (NGT) and 28 had type 2 diabetes.

2. Materials and methods {#sec2}
========================

2.1. Subjects and liver biopsies {#sec2.1}
--------------------------------

A liver biopsy was obtained during surgery in 28 type 2 diabetic and 12 nondiabetic subjects undergoing bariaric surgery. The liver samples were collected in RNA-Later (Ambion Inc., Applied Biosystems, Austin, TX, USA), and stored at −20 °C for total RNA extraction. Before surgery in each subject, after an overnight (12--14 h) fast, peripheral blood samples were obtained for determination of the routine blood chemistry plasma glucose, insulin and HbA~1c~ concentrations. The diabetic patients were asked to discontinue oral antidiabetic agents (metformin ± sulfonylureas) 48--72 h before the study.

The protocol was approved by the local ethics committee. The nature and purpose of the study were carefully explained to all participants before they provided written consent to participate.

2.2. Analytical procedures {#sec2.2}
--------------------------

Plasma glucose was measured by the glucose-oxidase technique (Analox GM-9), plasma insulin by electro-chemiluminescence (on a COBAS e411 instrument, Roche, Indianapolis, USA).

2.3. Gene expression {#sec2.3}
--------------------

RNA was extracted using Trizol (Life Technologies), cDNA was synthesized using reverse transcriptase (Applied Biosystems), and quantitative PCR was performed using SyBr Green (BioRad).

2.4. Statistical analyses {#sec2.4}
-------------------------

Data are given as mean ± SEM or median and \[interquartile range\]. Group differences were analyzed by Kruskall-Wallis and Mann--Whitney tests. *P* value \<0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Patient characteristics {#sec3.1}
----------------------------

The anthropomorphic and metabolic characteristics of the patients are shown in [Table 1](#tbl1){ref-type="table"}. T2D patients for whom HbA~1c~ was available were further separated into two groups, those with HbA~1c~ \<7.0% (53 mmol/mol), and those \>7.0%. Diabetic patients were older than NGT subjects, and the high HbA~1c~ group had lower average BMI than the other two groups.

3.2. Glucokinase expression is reduced in T2D {#sec3.2}
---------------------------------------------

In T2D patients overall, we identified a 43% reduction in *GCK* expression relative to NGT (0.57 ± 0.09 *vs* 1.00 ± 0.17, *p* = 0.028). However, we saw no change in expression of *G6PC*, *PCK1*, or *PCK2* (data not shown). When diabetic subjects were subdivided into HbA~1c~ categories, we found that the high HbA~1c~ group showed a substantial reduction in *GCK* compared to the NGT or low HbA~1c~ groups ([Figure 1](#fig1){ref-type="fig"}A). There were no significant changes in *G6PC*, *PCK1*, or *PCK2* expression among the three groups ([Figure 1](#fig1){ref-type="fig"}A). We also examined the glucose 6-phosphate transporter (encoded by *SLC37A4*), which was also not different between groups ([Figure 1](#fig1){ref-type="fig"}A).

3.3. Glucokinase expression is negatively correlated with HbA~1c~ {#sec3.3}
-----------------------------------------------------------------

Next we examined the association of gene expression with measures of glycemia. We found that *GCK* was significantly negatively correlated with HbA~1c~ and fasting glucose ([Figure 1](#fig1){ref-type="fig"}B--C). In contrast, *G6PC*, *PCK1*, *PCK2*, and *SLC37A4* were not associated with HbA~1c~ ([Figure 1](#fig1){ref-type="fig"}D--G) or fasting glucose (data not shown). Overall, these data suggest that progressive worsening of glycemia in type 2 diabetes is significantly associated with suppression of *GCK*, but not with expression of other gluconeogenic enzymes.

4. Discussion {#sec4}
=============

This study aimed to investigate contributors to the increase in HGP during diabetes. Consistent with prior reports, we find that liver expression of gluconeogenic enzymes alone cannot explain this phenotype [@bib5; @bib6]. On the other hand, our data indicate that suppression of hepatic *GCK* in diabetes patients: (i) explains the decreased GCK activity observed in previous studies [@bib8; @bib9; @bib10; @bib11; @bib12], and (ii) contributes to hyperglycemia quantitatively. The fact that defective hepatic GCK is sufficient to impair glycogen synthesis and increase gluconeogenesis was previously established in studies of liver metabolism in MODY2 patients [@bib13]. Moreover, it has been shown that restoration of hepatic GCK activity in Zucker diabetic fatty rats causes normalization of plasma glucose and suppression of endogenous glucose production [@bib14].

GCK is regulated by posttranslational and transcriptional mechanisms [@bib7]. Posttranslational regulation by glucose occurs through the glucokinase regulatory protein, which binds to GCK and causes its nuclear sequestration and protein stabilization. Dissociation of the two proteins occurs at high glucose concentrations, causing cytoplasmic translocation and accelerated degradation of GCK [@bib7; @bib15]. One of the limitations of our study was the lack of sufficient tissue to perform immunoblots. However, we found compelling evidence that frank diabetes is associated with a disruption in the transcriptional control of *GCK*, which is carried out by insulin [@bib16]. Major mediators of insulin\'s effect on *GCK* are the FOXO transcription factors. FOXOs are known for their role in promoting HGP during fasting [@bib17]. Under normal conditions, FOXOs are inactivated by insulin, through AKT-mediated phosphorylation and nuclear exclusion. Thus, a widely held explanation for excessive glucose production during diabetes is inappropriate activation of the hepatic FOXO pathway, due to insulin resistance. Two critical aspects of how FOXO promotes glucose production are by promoting *G6PC* [@bib17] and suppressing *GCK* [@bib18; @bib19; @bib20; @bib21]. This suggests that activated FOXOs may be responsible for excessive *GCK* suppression in diabetes. Consistent with this possibility, FOXO target *IGFBP1* was significantly elevated in the high HbA~1c~ patients (data not shown). How, then, can we reconcile the fact that *G6PC* was not also elevated? One possible explanation is that FOXOs\' effect on *GCK* is more potent than its effect on *G6PC*, as we have previously observed in mice [@bib21]. It is also possible that posttranslational modifications of FOXO that are induced by hyperglycemia, such as acetylation, affect some targets more than others [@bib22; @bib23].

In addition to its role in glucose homeostasis, hepatic GCK also plays a critical role in promoting *de novo* lipogenesis (DNL), a fact that has hindered the development of glucokinase activators as diabetes therapy [@bib24]. Indeed, previous work has shown that liver *GCK* expression is positively associated with liver triglyceride content and a marker of DNL in humans [@bib25]. Based on these findings, suppression of *GCK* -- as we observed in our severely diabetic patients -- might be expected to reduce lipogenic flux. This may seem paradoxical, as diabetic patients typically demonstrate hypertriglyceridemia. However, we observed no correlation of *GCK* to plasma triglyceride levels in our subjects (data not shown). A potential explanation is that DNL contributes to only a portion of circulating triglyceride levels [@bib26; @bib27; @bib28], the major fraction originating from reesterification of free fatty acids; the latter substrate circulates in increased amounts in type 2 diabetic patients due to insulin resistance of lipolysis [@bib29; @bib30].

There has been a long-standing interest in developing antidiabetic glucokinase activators [@bib24]. Given the narrow therapeutic window of these molecules, it may be important to increase our understanding of *GCK* dysregulation in the progression of T2D. This may be particularly valuable in designing individualized therapeutic regimens [@bib4].
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![Liver biopsies. (**A**) Gene expression in subjects with normal glucose tolerance (NGT) (n = 12) or type 2 diabetes with HbA~1c~ \< 7.0% (n = 7) or HbA~1c~ \> 7.0% (n = 17). \*\**p* \< 0.01 *vs* NGT and ^§§^*p* \< 0.01 *vs* T2D HbA~1c~ \< 7.0%, by Mann--Whitney test. (**B--G**) Correlations between gene expression and HbA~1c~ or fasting glucose levels.](gr1){#fig1}

###### 

Clinical characteristics.

  -------------------------------------------------------------------------------------------------------------------------------
                                                  NGT              All T2D              T2D\             T2D\
                                                                                        HbA1c \<7.0%     HbA1c \>7.0%
  ----------------------------------------------- ---------------- -------------------- ---------------- ------------------------
  N (F/M)                                         12 (12/0)        28 (7/21)            7 (3/4)          17 (3/14)

  Age (years)                                     39.5 ± 2.5       51.2 ± 1.3\*\*\*     48.4 ± 1.9\*\*   50.9 ± 1.9\*\*

  BMI (kg/m^2^)                                   50.4 ± 2.1       37.9 ± 1.6\*\*\*     45.8 ± 1.4       36.9 ± 2.0\*\*\*^,§^

  FPG (mmol/L)                                    5.24 ± 0.21      10.46 ± 0.74\*\*\*   6.5 ± 0.5\*      11.9 ± 0.95\*\*\*^,§§^

  FPI (pmol/L)                                    129.9 \[45.5\]   119.1 \[95.6\]       168.6 \[89.3\]   111.6 \[108.6\]

  HbA~1C~ (%)[a](#tbl1fna){ref-type="table-fn"}   5.8 ± 0.2        8.4 ± 0.37\*\*       6.3 ± 0.2\*      9.3 ± 0.3\*\*^,§§§^
  -------------------------------------------------------------------------------------------------------------------------------

\*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001 versus NGT and ^§^P \< 0.05, ^§§^P \< 0.01, ^§§§^P \< 0.001 *vs* T2D HbA~1c~\<7.0%, by Mann--Whitney test.

Available for 5 out of 12 NGT subjects and 24 out of 28 T2D patients.
